-- Nektar Therapeutics (NKTR) said Monday that data from a 16-week extension period of its phase 2b study of rezpegaldesleukin showed a "deepening of response" in patients with severe-to-very-severe alopecia areata.
Wedbush Securities lifted its price target for Nektar Therapeutics' shares to $95 from $70 while maintaining the stock's neutral rating.
Shares of Nektar jumped 22%, with intraday trading volume of nearly 3.4 million, up from a daily average of about 1.1 million.
Compass Pathways (CMPS), GH Research (GHRS), and other psychedelic companies' shares were up on Monday, after US President Donald Trump signed an executive order Saturday to expedite access to treatments for patients with serious mental illness.
Shares of Compass Pathways surged 49% as intraday trading volume soared to over 29 million from a daily average of about 3.05 million.
GH Research shares advanced 14% as intraday trading volume jumped to over 953,700 from a daily average of roughly 192,000.
Price: $103.50, Change: $+18.64, Percent Change: +21.97%